Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11523-015-0358-9.pdf
Reference96 articles.
1. Kohler J, Schuler M (2013) Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 36(9):510–8
2. Herbst RS, Bunn PA Jr (2003) Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 9(16 Pt 1):5813–24
3. Spiro SG, Silvestri GA (2005) One hundred years of lung cancer. Am J Respir Crit Care Med 172(5):523–9
4. Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3(8):448–57
5. Zhang Z, Stiegler AL, Boggon TJ et al (2010) EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1(7):497–514
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence;Cancer Letters;2024-07
2. A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol;2024-04-16
3. Novel small molecule inhibitors targeting renal cell carcinoma: Status, challenges, future directions;European Journal of Medicinal Chemistry;2024-03
4. Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer;International Journal of Pharmaceutics;2024-01
5. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials;Journal of Clinical Pharmacy and Therapeutics;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3